About us
Services & Solutions
Chemistry DMPK Discovery Biology Oncology Pharmacology Biologics
Medicinal Chemistry Peptide Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
In Vivo PK and TK In Vitro ADME Bioanalytical Service Exploratory Toxicity In Rodents, Dogs and Monkeys Large Molecules Capabilities Bioanalytical Instruments
Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Immunology Inflammation Metabolic NASH/MASH Respiratory Neuroscience
Systematic Antibody Discovery Service
Process R&D Scale Up Synthesis DS Manufacturing
Flow Chemistry Sugar Chemistry Peptide Chemistry Preparative Purification Capacity Process Safety Assessment
Synthetic and Scale Up Chemistry Parallel Synthesis
Flow Chemistry Kilo and Pilot Scale Production RSM and Intermediates Manufacturing QA EHS
Pre-Formulation Formulation, Analytical and Process Development Drug Product Manufacturing
Bioavailability Enhancement Modified Release
Commercial Manufacturing
Platforms
News & Resources
Careers
Contact us
CN EN
×

news

Company News Events Insights Webinars Virtual Tours

Congratulations To GenFleet Therapeutics For Selective CDK9 Inhibitor GFH009 Injection Approved For Clinical Trial by NMPA

CDK9 inhibitor GFH009 Injection has been approved by the CDE (Center for Drug Evaluation), NMPA for clinical trials | BioDuro-Sundia | Moving You Forward
December 21, 2020

BioDuro & Silexon Form Strategic Collaboration to Develop New Anti-Cancer Drugs

BioDuro and Silexon collaborate on new anti-cancer drugs, leveraging advanced NASH models for accelerated preclinical testing and development | BioDuro-Sundia
December 03, 2020

Congratulations! Innocare‘s Orelabrutinib has been approved by NMPA for Commercial in China!

InnoCare Pharma's BTK inhibitor, Orelabrutinib, receives NMPA approval for commercialization in China, targeting mantle cell lymphoma and chronic lymphocytic ...
November 22, 2020

Congratulations to TaiGen’s Flu Antiviral Drug TG-1000 for Receiving FDA approval of IND

TaiGen Biotechnology has received FDA approval for the clinical trial application of their new influenza antiviral drug, TG-1000, targeting influenza A and B.
November 02, 2020

Congratulations to Longwood Biopharmaceuticals for LW402 Accepted for Clinical Trial

BioDuro-Sundia assists Longwood Biopharmaceuticals to complete the API production research of LW402 tablets | For the treatment of Rheumatoid Arthritis.
September 26, 2020
Total 85 12...567891011...1617
Subscribe to BioDuro-Sundia
Receive our newsletter and information on upcoming events
Your trusted partner from drug discovery and
development to commercialization

Home

About us

Services & Solutions

Platforms

News & Resources

Careers

Contact us

Explore

Discovery

Drug Substance

Drug Product

© 2023 BioDuro-Sundia. All rights reserved
Terms of Use Privacy Policy
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all